The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Major retailers can tailor prices based on customer data including location, demographics or shopping history, the US Federal Trade Commission said in initial study findings, raising concerns ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
In response to the findings of FTC, UnitedHealth’s OptumRx defended its practices while claiming it has helped patients save money on medications, noted Fortune. Meanwhile, at the same time, CVS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback